Andrew Sharabi

Dr. Andrew Sharabi is a physician scientist and board-certified radiation oncologist at UC San Diego Moores Cancer Center. He holds the position of Clinical Professor in the Department of Radiation Medicine and Applied Science within the School of Health Sciences at the University of California San Diego. Dr. Sharabi serves as Director of the Center for Precision Radiation Medicine and Radiation Medicine Core Facility at Moores Cancer Center and is Chair of the American Society of Therapeutic Radiology and Oncology (ASTRO) Education Committee - Immunotherapy Track.

Dr. Sharabi's educational background includes:

• B.S. in Bioengineering from University of California at San Diego (2001)
• Ph.D. in Immunology from Baylor College of Medicine (2009)
• M.D. from Baylor College of Medicine (2010)
• Residency in Radiation Oncology at Johns Hopkins Hospital (2015)

Dr. Sharabi is a recognized expert on the effects of radiation on the immune system and the ability of radiation therapy to synergize with checkpoint blockade immunotherapy. His research focuses on developing novel immunotherapies and strategies to combine radiation with immunotherapy, particularly for head and neck cancers and prostate (genitourinary) cancers. He treats patients with advanced radiotherapy techniques including intensity modulated radiotherapy (IMRT), image-guided radiotherapy (IGRT), 4-D computed tomography, and Stereotactic Body Radiation Therapy (SBRT). His work has significant implications for improving cancer treatment outcomes through the strategic combination of radiation and immunotherapy.

Analysis of Dr. Sharabi's recent publications reveals a strong focus on the intersection of radiation oncology and immunotherapy. His research spans multiple cancer types, with particular emphasis on head and neck squamous cell carcinoma (HNSCC) and genitourinary cancers. Key themes include the sequencing of radiation and immunotherapy, mechanisms of immune activation following radiation, biomarker development for treatment personalization, and strategies to overcome resistance to combined modality therapy. His work frequently appears in high-impact journals including Nature Communications and Lancet Oncology, demonstrating the significance of his contributions to the field.

Dr. Sharabi has received numerous prestigious awards and honors throughout his career:

• Association of Residents in Radiation Oncology (ARRO) Educator of the Year Award (2020)
• Academy of Clinician Scholars Whitehill Award for Excellence in Teaching (2019)
• American Cancer Society (ACS) Cancer Care Champion - Radiation Oncologist of the Year (2019)
• UCSD ACTRI KL2 Translational Science Award (2017)
• Multiple awards from the American Society for Radiation Oncology (ASTRO) including the Roentgen Resident/Fellow Research Award (2015)

As Principal Investigator, Dr. Sharabi leads multiple NIH-funded research projects including 'Investigating Mechanisms of Hyperprogression on Anti-PD-1 Immunotherapy' (NIH R21CA256360) and 'Role of B-cell mediated anti-tumor antibodies in responses to radiation and immunotherapy in HNSCC' (NIH/NIDCR R01DE028563). His research program combines basic science investigations with clinical trials, bridging the gap between laboratory discoveries and patient care. While specific information about his advisees is not provided in the available materials, his leadership roles suggest he mentors numerous students, residents, and fellows in radiation oncology and cancer research.

Dr. Sharabi directs the Center for Precision Radiation Medicine and Radiation Medicine Core Facility at Moores Cancer Center, where his NIH-funded laboratory focuses on developing novel immunotherapies and strategies to combine radiation with immunotherapy. His research team likely includes postdoctoral fellows, graduate students, research technicians, and clinical collaborators working across disciplines to advance cancer treatment through innovative combinations of radiation and immunotherapy.